AUS
NZ
UK
CA
USA
IND
_06_19_2026_12_34_15_139937.jpg)
Highlights
- Telix Pharmaceuticals plans to double sales with new cancer treatment products.
- Illuccix sales expected to expand with upcoming regulatory approvals.
- Nasdaq listing planned without raising new capital or issuing shares.
Telix Pharmaceuticals (ASX:TLX) has announced ambitious plans to significantly increase its sales over the next few years, driven by the introduction of three new cancer treatment products. The Melbourne-based company, known for its advancements in nuclear medicine, expects these new therapies to play a key role in boosting its revenue as it prepares for a secondary listing on the Nasdaq.
Telix’s chief executive, Christian Behrenbruch, emphasized the company’s growth potential, highlighting that it could see its sales double over the next few years as these new treatments for prostate, kidney, and brain cancers enter the market. The company currently generates most of its revenue from its prostate cancer imaging drug, Illuccix, particularly in North America.
Nuclear medicine, the field in which Telix operates, involves the use of radioisotopes—radioactive chemical elements that target cancer cells for treatment. Dr. Behrenbruch believes that nuclear medicine is maturing and coming into its own as a powerful tool in cancer treatment, with Telix at the forefront of this emerging industry.
Expansion and Regulatory Approvals
Telix anticipates further growth from expanding the sales of Illuccix into new regions. European regulators are expected to approve the drug in early 2024, with the United Kingdom and Brazil following suit. This international expansion is seen as a critical driver for increasing the company’s revenue, alongside the anticipated launch of three new cancer therapies in the first half of 2024.
In addition to its sales expansion, Telix plans to list American Depositary Shares on the Nasdaq, giving US investors and its employees an opportunity to own equity in the company. However, this listing will not involve raising fresh capital or issuing new shares, as Telix aims to fund future acquisitions from a previous $650 million raised through convertible bonds.
Strong Financial Performance and Growth Plans
Telix has already shown strong financial performance, reporting a 55% increase in third-quarter revenue to $201 million, driven largely by sales of Illuccix in the US. Total revenue for the first nine months of 2024 reached $565 million, with full-year revenue guidance reaffirmed at $745 million to $776 million. Despite challenges in international markets, with only $6 million in revenue generated outside the US, the company is optimistic about its future growth.
The company’s shares have seen remarkable growth, doubling in value in 2024 alone. The stock recently traded at $21.73, nearing its record high of $22.08. Telix’s long-term strategy includes expanding its presence in the US, where it has been acquiring radiopharmacy networks as part of a $1 billion acquisition spree over the past two years.
Telix is positioning itself as a major player in the global market for cancer treatments, particularly those involving nuclear medicine. With regulatory approvals on the horizon and new products set to launch, the company is well-placed for continued growth in the coming years.
